NICE draft guidance refuses pembrolizumab plus axitinib combination

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE stated that there was uncertainty about the long-term […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Pilot study of radiation therapy plus pembrolizumab for kidney cancer

A recent publication in the American Journal of Clinical Oncology this month reports on part of an exploratory study to look at the effect of radiotherapy alone or in combination with pembrolizumab on the immune system, and to determine the efficacy of this treatment in patients with solid tumours. This is the first study to […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]

read more

Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer

A recent phase 1b clinical trial investigated the use of pegilodecakin in combination with anti-PD-1 monoclonal antibodies nivolumab or pembrolizumab. The combination showed a “favourable” response in patients with non-small cell lung cancer and kidney cancer. Pegilodecakin works by stimulating the survival, proliferation and “killing” potential of CD8+ T cells, which can recognise and destroy […]

read more

European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase 3 KEYNOTE-426 trial, the European Commission has today approved pembrolizumab (anti-PD-1 therapy) in combination with axitinib (tyrosine kinase inhibitor) for patients with untreated, advanced renal cell carcinoma (RCC). The KEYNOTE-426 trial demonstrated a reduced risk of death by 47% with the combination compared to sunitinib in patients […]

read more

European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of pembrolizumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first combination of immunotherapy (pembrolizumab) with a tyrosine kinase inhibitor (axitinib) to receive a […]

read more
Showing 1 to 10 of 39 results
  TOP